April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Electron Beam Salvage Radiation Therapy for Squamous Carcinoma of the Conjunctiva and Cornea
Author Affiliations & Notes
  • Gerardo F. Graue-Moreno
    New York Eye Cancer Center, New York, New York
  • Paul T. Finger
    New York Eye Cancer Center, New York, New York
  • Lawrence B. Tena
    Beth Israel Comprehensive Cancer Center, New York, New York
  • Footnotes
    Commercial Relationships  Gerardo F. Graue-Moreno, None; Paul T. Finger, None; Lawrence B. Tena, None
  • Footnotes
    Support  The Eye Cancer Foundation, Inc., supported this study.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4534. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gerardo F. Graue-Moreno, Paul T. Finger, Lawrence B. Tena; Electron Beam Salvage Radiation Therapy for Squamous Carcinoma of the Conjunctiva and Cornea. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4534.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To describe our technique and preliminary results using electron beam radiation as rescue therapy for recalcitrant squamous cell carcinoma of the conjunctiva and cornea (SCC).


A retrospective review comprised of an interventional case series of patients with pathologically confirmed diagnosis of SCC, who had failed multiple standard treatments and underwent electron beam radiation therapy (EBRT). Outcomes, radiation-related complications and adverse effects were documented. Mortality and local control rates were calculated by the Kaplan-Meier survival probability method.


Eight patients met the inclusion criteria, of this 6 (75%) where male and 2 (25%) where female, ages ranging from 38 to 65 years (mean 50 years). One tumor (12.5%) was classified as T2N0M0, 6 (75%) as T3N0M0 and 1 (12.5%) as T4N0M0. Follow-up from EBRT ranged from 3 to 72 months (mean 30.25 months). The most common side effect was erythema and edema of the eyelids with diffuse transient eyelash loss, seen in all patients. Tumor local control and regression after EBRT was noted in 6 patients (75%), recurrence in 2. There were neither metastatic spread nor tumor-related deaths.


We report a small case series where local tumor control was achieved with electron beam radiation therapy for recalcitrant SCC. This approach may be considered for patients who fail conventional therapy.  

Keywords: tumors • radiation therapy • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.